New drug could get heart surgery patients home days earlier

NCT ID NCT07357675

Not yet recruiting Disease control Sponsor: EBI Anti Sepsis BV Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether a drug called EA-230 can help people recover faster after coronary artery bypass surgery. About 300 adults scheduled for elective bypass surgery will receive either EA-230 or a placebo during the operation. Researchers will measure how long participants stay in the ICU and hospital, and whether they have fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EA-230 (a drug given intravenously during surgery)
What this could lead to: If it works, EA-230 could help people recover faster after bypass surgery, spending less time in the ICU and hospital with fewer serious complications.
What could go wrong: This is an early Phase 3 trial, so results are not yet proven. The drug may not work as well in a larger group, and there is always a risk of side effects not seen in earlier studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY BYPASS GRAFT SURGERY (CABG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY BYPASS GRAFT SURGERY (CABG) CORONARY ARTERY DISEASE (CAD)

Contacts and locations

Locations

MAYO clinic

Rochester, Minnesota, 55905, United States
Medisch Spectrum Twente

Enschede, Netherlands
RadboudUMC

Nijmegen, Netherlands
St Thomas' Hospital

London, United Kingdom
UPMC

Pittsburgh, Pennsylvania, 15213, United States
UZ Gent

Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.